Comparison
BPC-157 vs. KPV
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Healing
CAS no.
137525-51-0
67727-97-3
Molecular weight
1419.5 g/mol
342.4 g/mol
Half-life
4 h
no data
Sequence
GEPPPGKPADDAGLVKPVMechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
KPV
KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.
Evidence base
Highest evidence
Animal model
Animal model
Studies
5
4
of which in humans
0
0
Effects recorded
4
5
Open conflicts
2
0
Documented adverse events
2
0
Legal status
Full entries
Frequently asked questions
- What is the difference between BPC-157 and KPV?
- BPC-157 is classified as "Healing", while KPV is classified as "Healing". BPC-157: Synthetic pentadecapeptide (15 amino acids) derived from a sequence of a gastric-juice protein. Studied predominantly in animal models on healing and protective processes — controlled human trials are rare and limited in scope. KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, BPC-157 or KPV?
- The highest available evidence level is "Animal model" for BPC-157 and "Animal model" for KPV. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of BPC-157 and KPV in Germany and the United States?
- Germany: BPC-157 — Unapproved, KPV — Unapproved. United States: BPC-157 — Research only, KPV — Research only. These are factual summaries with source and review date on the individual pages.